Literature DB >> 18097448

Immunological aspects of cancer chemotherapy.

Laurence Zitvogel1, Lionel Apetoh, François Ghiringhelli, Guido Kroemer.   

Abstract

Accumulating evidence indicates that the innate and adaptive immune systems make a crucial contribution to the antitumour effects of conventional chemotherapy-based and radiotherapy-based cancer treatments. Moreover, the molecular and cellular bases of the immunogenicity of cell death that is induced by cytotoxic agents are being progressively unravelled, challenging the guidelines that currently govern the development of anticancer drugs. Here, we review the immunological aspects of conventional cancer treatments and propose that future successes in the fight against cancer will rely on the development and clinical application of combined chemo- and immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097448     DOI: 10.1038/nri2216

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  522 in total

1.  Fish oil supplementation improves neutrophil function during cancer chemotherapy.

Authors:  Sandro J R Bonatto; Heloisa H P Oliveira; Everson A Nunes; Daniele Pequito; Fabiola Iagher; Isabela Coelho; Katya Naliwaiko; Marcelo Kryczyk; Gleisson A P Brito; João Repka; Luciano V Sabóia; George Fukujima; Philip C Calder; Luiz C Fernandes
Journal:  Lipids       Date:  2011-12-11       Impact factor: 1.880

Review 2.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

3.  Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.

Authors:  Douglas W McMillin; Jake Delmore; Joseph M Negri; Matthew Vanneman; Shohei Koyama; Robert L Schlossman; Nikhil C Munshi; Jacob Laubach; Paul G Richardson; Glenn Dranoff; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

4.  Recent successes of cancer immunotherapy: a new dimension in personalized medicine?

Authors:  Christophe Caux; Laurence Zitvogel
Journal:  Target Oncol       Date:  2012-02-15       Impact factor: 4.493

Review 5.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

6.  Targeting dendritic cell metabolism in cancer.

Authors:  Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2010-08       Impact factor: 53.440

Review 7.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 8.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

Review 9.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

Review 10.  Tumor lysate-loaded biodegradable microparticles as cancer vaccines.

Authors:  Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem
Journal:  Expert Rev Vaccines       Date:  2014-01       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.